IN SILICO IDENTIFICATION OF TARGET PALINDROMIC GENES AS POTENTIAL DRUG TARGETS IN BREAST CANCER THERAPY
Authors: Awofisayo Oladoja 
Published: November 2020

Objectives: Diabetes is increasingly recognized as a serious, worldwide public health concern. By early identifying those at risk to develop diabetes and if confirmed to be at pre-diabetes stage adequate care provided for them through lifestyle interventions or even hypoglycemic medications if necessary, thus delaying or preventing their progression to diabetic status. The study aims at assessing the risk of developing type 2 diabetes mellitus (T2DM) among healthy non-diabetic Sudanese in Khartoum city. Breast cancer (BC) is the most common cancer worldwide prevalent among women with more than one million cases and is second only to lung cancer.
Methods: The identification of the sequences based on the unique tetramers GCAC, GTCA were selected from experimental work. The16 base pair DNA regulatory sequences of which the motifs area part of containing these motif in genes implicated in cancer CAGE1 (AAGCTGTCATTA), BRCA1(GACTGAGTCAA), ABCB1(CTCTAAGTCAT), ABCB5 (GATATGTTAAAGC) and ABI1(CTTCTGGGAA)  were then selected as novel putative targets in breast cancer therapy based on their selectivity on the BC oncogenes which are not found in the normal human genome 1-23 and the sex chromosomes X and Y were obtained via computational analysis.
Results: The single copy base pairs which will be potential drug targets as anticancer drugs were finally obtained as CTGTTATGACTGAGTCAA, CAGE1 with the 17 base pairs CATAAAAGC TGTCATTA and ABCB1 TTGCCAA CTCTAAGT CAT.
Conclusion: It is Possible that the in silico discovery of putative anti breast cancer targets of importance in the genome.
Peer Review History:
Received 18 July 2020; Revised 25 September; Accepted 12 October, Available online 15 November 2020
UJPR follows the most transparent and toughest ‘Advanced OPEN peer review’ system. The identity of the authors and, reviewers will be known to each other. This transparent process will help to eradicate any possible malicious/purposeful interference by any person (publishing staff, reviewer, editor, author, etc) during peer review. As a result of this unique system, all reviewers will get their due recognition and respect, once their names are published in the papers. We expect that, by publishing peer review reports with published papers, will be helpful to many authors for drafting their article according to the specifications. Auhors will remove any error of their article and they will improve their article(s) according to the previous reports displayed with published article(s). The main purpose of it is ‘to improve the quality of a candidate manuscript’. Our reviewers check the ‘strength and weakness of a manuscript honestly’. There will increase in the perfection, and transparency.
Received file

Average Peer review marks at initial stage: 5.5/10
Average Peer review marks at publication stage: 7.0/10
Reviewer(s) detail:
Dr. Nkechi Obiofu Ezenobi, University of Port Harcourt, Nigeria, nkechi.ezenobi@uniport.edu.ng
Shahinga Vanji, World Academy of Medical Sciences, Iran,  shahin.gavanji@khuisf.ac.ir
Comments of reviewer(s):

Similar Articles:
IN SILICO LIGAND-BASED 2D PHARMACOPHORE GENERATION FOR H+/K+ ATPASE INHIBITORS